OncoMed to Present Clinical Data for Anti-RSPO3 and Anti-DLL4/VEGF Bispecific Antibody at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
15 nov. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present first-in-human data from its Phase 1 clinical trials of...
OncoMed Pharmaceuticals Reports Third Quarter 2016 Financial Results
01 nov. 2016 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Ends Quarter with $207 Million Cash Enrollment Complete in Phase 2 Trials for Demcizumab and Tarextumab;On Track for Data in 1H 2017 OncoMed Management to Host Conference Call/Webcast this...
OncoMed Pharmaceuticals to Report Financial Results for the Third Quarter on Tuesday, November 1, 2016
26 oct. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a biopharmaceutical company focused on discovering and developing novel anti-cancer...
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress
10 oct. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
COPENHAGEN, Denmark and REDWOOD CITY, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) today announced the presentation of interim clinical data from its...
OncoMed to Present Clinical Data for Wnt Inhibitors at the ESMO 2016 Congress
29 sept. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 29, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present interim data from Phase 1b clinical trials of the company’s Wnt...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
01 sept. 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Management to Present at Two Upcoming Investment Conferences
31 août 2016 16h10 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 PINNACLE Clinical Trial of Tarextumab in Small Cell Lung Cancer
30 août 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
23 août 2016 16h02 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock
18 août 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...